Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 5.2% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (AMLX) is currently advancing its lead candidate, avexitide, through pivotal trials for post-bariatric hypoglycemia and ALS treatment. The stock had a bearish movement today.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 5.2% on May 12, 2026 16:16

• A Discounted Cash Flow (DCF) analysis suggests AMLX is significantly undervalued, but its Price-to-Book (P/B) ratio indicates overvaluation compared to industry peers.
• Despite positive developments like completing enrollment for a pivotal trial and initiating an Expanded Access Program, AMLX's stock is trading below consensus targets and fair value estimates, leading to a large valuation gap.
• Analysts have provided varied ratings on AMLX, reflecting differing outlooks on the company's stock performance.
• The overall bearish movement in the healthcare sector, as evidenced by other healthcare stocks experiencing significant decreases in the pre-market session, could have contributed to AMLX's downward trend today.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge?

Amylyx Pharmaceuticals (AMLX) has surged 220.2% over the past year, prompting an evaluation of its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued at $14.73, with an estimated intrinsic value of $48.59. However, its Price-to-Book (P/B) ratio of 5.99x indicates it is overvalued compared to the industry average of 2.70x, pointing to differing perspectives on its true worth.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amlx/amylyx-pharmaceuticals/news/is-it-too-late-to-consider-amylyx-pharmaceuticals-amlx-after

Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap

Amylyx Pharmaceuticals (AMLX) is advancing its lead candidate, avexitide, through the pivotal Phase III LUCIDITY trial for post-bariatric hypoglycemia (PBH), with data expected next quarter. The company has also initiated an expanded access program for avexitide. Despite recent stock weakness, its shares are trading significantly below the consensus target and Simply Wall St's fair value estimate, indicating a large valuation gap.

https://www.sahmcapital.com/news/content/amylyx-readies-avexitide-for-pbh-with-pivotal-trial-and-valuation-gap-2026-05-10

Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN)

Healthcare sector analysts have recently provided new ratings for Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX), and AMN Healthcare Services (AMN). Amylyx and Annexon Biosciences received Buy ratings with significant upside potential from H.C. Wainwright, while AMN Healthcare Services was given a Hold rating by William Blair. These ratings reflect varied outlooks on the companies' stock performance.

https://www.theglobeandmail.com/investing/markets/stocks/AMN/pressreleases/1828237/analysts-offer-insights-on-healthcare-companies-amylyx-pharmaceuticals-inc-amlx-annexon-biosciences-annx-and-amn-healthcare-services-amn/

12 Health Care Stocks Moving In Friday's Pre-Market Session

This article identifies 12 healthcare stocks experiencing significant movement during Friday's pre-market session. The report highlights both gainers and losers, providing details on their stock price changes, market capitalization, and recent Q1 earnings announcements where applicable. Traws Pharma, Amylyx Pharmaceuticals, Celldex Therapeutics, InMed Pharmaceuticals, Progyny, and Artiva Biotherapeutics saw increases, while Sensus Healthcare, Absci, Amphastar Pharma, Capricor Therapeutics, Organogenesis Holdings, and Artivion experienced decreases.

https://www.benzinga.com/insights/movers/26/05/52405500/12-health-care-stocks-moving-in-fridays-pre-market-session

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Amylyx Pharmaceuticals reported its first-quarter 2026 financial results, highlighting that enrollment for the pivotal Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia is complete, with topline data expected in Q3 2026. The company also initiated an Expanded Access Program for avexitide and is advancing AMX0114 for ALS, with a cash runway projected into 2028.

https://www.biospace.com/press-releases/amylyx-pharmaceuticals-reports-first-quarter-2026-financial-results

Trending Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Down 9.9% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Down 5.2% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.7% Today

Circle Internet Group ($CRCL) Stock Forecast: Down 5.5% Today

KLA-Tencor Corporation ($KLAC) Stock Forecast: Down 6.0% Today

Humana Inc. ($HUM) Stock Forecast: Up 5.1% Today

Zebra Technologies Corporation ($ZBRA) Stock Forecast: Up 14.7% Today

Philip Morris International Inc ($PM) Stock Forecast: Up 5.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 10.1% Today

CDW Corporation ($CDW) Stock Forecast: Down 5.1% Today

Amylyx Pharmaceuticals Price History

07.03.2026 - AMLX Stock was up 5.0%

• AMLX shares surged by 6.66% on April 6, driven by positive investor sentiment and analyst recommendations pointing towards a potential upside.
• The 7.8% drop following the earnings report showing $0 revenue and concerns over stock dilution from a shelf filing led to a brief decline in the stock price.
• The completion of enrollment and dosing for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia is a crucial milestone for AMLX, with the outcome expected to shape the company's future revenue prospects and investment narrative.
• Overall, the bullish movement today can be attributed to a mix of positive analyst outlook, milestone achievements in clinical trials, and short-term market reactions to earnings and dilution concerns.

30.02.2026 - AMLX Stock was down 5.5%

• The bearish movement in AMLX's stock price today can be attributed to a realignment of holdings by a major investment firm, resulting in the firm reporting 0% beneficial ownership of AMLX common stock. This change may have caused uncertainty among investors, leading to a sell-off of the stock.
• Despite analysts on Wall Street maintaining a bullish sentiment on AMLX and reiterating Buy ratings with optimistic price targets, the sudden change in the investment firm's ownership status likely overshadowed these positive recommendations.
• Additionally, the discontinuation of the ORION program for AMX0035, as highlighted in recent SEC filings, could have raised concerns among investors about the company's future pipeline and potential revenue streams, contributing to the bearish market movement.

12.04.2026 - AMLX Stock was down 5.2%

• A Discounted Cash Flow (DCF) analysis suggests AMLX is significantly undervalued, but its Price-to-Book (P/B) ratio indicates overvaluation compared to industry peers.
• Despite positive developments like completing enrollment for a pivotal trial and initiating an Expanded Access Program, AMLX's stock is trading below consensus targets and fair value estimates, leading to a large valuation gap.
• Analysts have provided varied ratings on AMLX, reflecting differing outlooks on the company's stock performance.
• The overall bearish movement in the healthcare sector, as evidenced by other healthcare stocks experiencing significant decreases in the pre-market session, could have contributed to AMLX's downward trend today.

25.02.2026 - AMLX Stock was up 5.4%

• An investment firm maintains a "Buy" rating for AMLX with a high price target, suggesting a notable potential for growth and enhancing investor confidence.
• The conclusion of enrollment in the crucial Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia (PBH) demonstrates advancement in a promising treatment, garnering positive attention in the market.
• Amylyx's updated corporate presentation outlining Phase 3 trial progress and strong financial standing, with funds available until 2028, has further encouraged investors.
• The successful completion of patient enrollment in the Phase 3 LUCIDITY trial, alongside positive updates on other research endeavors and a solid financial position, has solidified the market's positive outlook on Amylyx Pharmaceuticals.

29.03.2026 - AMLX Stock was down 5.1%

• The downward movement in AMLX stock today might be due to profit-taking by investors following several price target upgrades by different financial institutions. It is possible that traders decided to sell to secure profits after positive changes were made to the price targets.
• Despite the positive outlook from analysts and the excitement surrounding the Phase 3 LUCIDITY study data for avexitide, the market response today could indicate a short-term decline in the stock price.
• The reduction in the Co-CEO and Director's 2025 compensation compared to the previous year may also play a role in the negative sentiment towards the stock, potentially raising concerns about internal stability or performance expectations within the company.

28.03.2026 - AMLX Stock was down 5.2%

• The bearish movement in AMLX stock today could be attributed to the significant decrease in compensation for both Co-CEOs and Directors, Justin Klee and Joshua Cohen, as revealed in the recent SEC DEF14A filings. This unexpected decrease in executive pay may have raised concerns among investors about the company's financial performance or future prospects.
• Investors might be reacting to the upcoming Q3 2025 earnings preview, anticipating potentially disappointing financial results. The market sentiment could be influenced by expectations set by analysts and insiders' activities.
• Insider trading activities, hedge fund movements, and analyst ratings could have also contributed to the negative market sentiment surrounding AMLX stock, leading to the bearish movement observed today.

28.03.2026 - AMLX Stock was down 5.1%

• An increased price target for AMLX was influenced by a reduced expense forecast, potentially boosting investor confidence initially.
• However, concerns arose over the reduced compensation of the Co-CEO and Director in 2025, prompting doubts about the company's financial well-being and future prospects, leading to the bearish market movement.
• The impending Q3 2025 earnings preview may also be contributing to investor unease and stock selling pressure.
• In summary, despite positive adjustments to the price target, the news about reduced executive compensation and the upcoming earnings report could have dampened optimism, resulting in the decline of AMLX stock.

06.03.2026 - AMLX Stock was up 5.1%

• AMLX experienced a notable 3.52% increase in share price on April 2nd, despite reporting $0 revenue in its recent earnings.
• The positive market response could be linked to the successful enrollment and dosing completion of its pivotal Phase 3 LUCIDITY trial, marking a significant achievement for the company.
• Investor confidence in the potential success of avexitide for post-bariatric hypoglycemia, demonstrated by the trial enrollment completion, likely influenced the bullish movement.
• Concerns about stock dilution after the shelf filing appear to have been outweighed by favorable developments in the company's clinical trials, prompting the upward trend in the stock price.

07.04.2026 - AMLX Stock was down 6.9%

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

14.03.2026 - AMLX Stock was up 5.3%

• The bullish movement in AMLX stock could be attributed to the selection of AMX0318 as a new development candidate, indicating progress in the company's pipeline for treating neurodegenerative diseases.
• The upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference might have generated positive investor sentiment, as it provides a platform for the company to showcase its innovative therapies and potential market opportunities.
• Despite the investigation into potential breaches of fiduciary duties by insiders, investors seem optimistic about the company's future prospects, possibly due to the focus on addressing diseases with high unmet needs and the positive market analysis reports.
• Overall, the combination of positive corporate developments, upcoming conference presentation, and market analysis highlighting growth potential could have fueled the bullish momentum in AMLX stock today.

10.03.2026 - AMLX Stock was down 5.1%

• The bearish movement in AMLX's stock price could be attributed to the ongoing investigation into potential breaches of fiduciary duties by the company's officers and directors. This uncertainty may have led to a lack of investor confidence in the stock.
• Additionally, despite the positive news of AMLX's participation in the 25th Annual Needham Virtual Healthcare Conference to showcase its development candidates, the market may have reacted negatively to the lack of concrete updates or significant announcements during the event.
• The insider trading activities disclosed in the SEC filings, including stock sales for tax obligations and gifts, might have also contributed to the downward pressure on AMLX's stock price as investors may interpret these actions as a lack of long-term confidence in the company's prospects.
• Overall, the combination of legal investigations, lack of significant updates from the healthcare conference, and insider trading activities could have collectively influenced the bearish market movement in AMLX today.

17.03.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) received a "Moderate Buy" recommendation from brokerages, indicating positive sentiment towards the stock.
• The company reported quarterly earnings that slightly beat analyst estimates, contributing to the bullish movement in the stock.
• Insider transactions, such as recent sales by the CEO, and adjustments in holdings by institutional investors may have influenced market confidence in the company's future prospects, driving the bullish movement in the stock.